



PRESS RELEASE

DR RAFFAELE PETRONE AND DR FULVIO CITAREDO APPOINTED CHAIRMAN AND DIRECTOR RESPECTIVELY OF THE SUBSIDIARY THERAMETRICS HOLDING AG

Capua, 14 May 2015 – Pierrel S.p.A. (the “**Company**”) discloses that the Meeting of shareholders of the subsidiary THERAMetrics holding AG, a Swiss company active in pharmaceutical research, specialising in new applications for existing pharmaceuticals to treat rare diseases, and which acts as parent company of the Tech-driven Contract Research & Development Organization Division (TCRDO) of the Pierrel Group and whose shares are listed on the SIX Swiss Exchange, meeting on 13 May past appointed, amongst other things, a new Board of Directors comprising, amongst others, Dr Raffaele Petrone, Chairman of the Board of Directors of the Company, and Dr Fulvio Citaredo, CEO of the Company. During the same Meeting of the Swiss subsidiary, Dr Petrone was also confirmed in the position of Chairman of the Board of Directors.

The newly elected Board of Directors of THERAMetrics holding AG will remain in office until the approval of the financial statements for the year ended 31 December 2015.

For further information refer to the web site of THERAMetrics holding AG (www.therametrics.com).

* * *

Pierrel S.p.A. is a global supplier to the pharmaceutical, biopharmaceutical and life science industries, specialising in the discovery of medicinal product candidates and the repositioning of existing drugs for new therapeutic indications and clinical research (TCRDO Division), pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division).

Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years’ experience in the pharmaceutical sector, being one of Europe’s leading producers of local and dental anaesthetics. The TCRDO Division, working across Europe and the US, is recognised internationally for its research and development into tech based clinical research innovations with its Drug Repositioning and Repurposing System (“**DRR2.0**”) and Integrated Clinical Development Services (“**ICDS**”) for the pharmaceutical, biotechnology and biomedical industries. The parent company of the TCRDO Division (**THERAMetrics holding AG**, listed in the Swiss stock exchange) holds the innovative interactive **DRR2.0** platform, which runs on a database of 24 million scientific publications (being virtually all of those available in the field of biomedical literature), of over 4,900 drugs and of 9,400 illnesses. With this data, never before collected in one place and stored in the cloud, the Search and Match algorithm can show a researcher not only the candidate drug but also a detailed road map with indications of possible second medical use. The database can be accessed by molecule or by illness. Pierrel also has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines. The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe.

The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

For further information:

Pierrel S.p.A.

Investor Relations

Dr Raffaele Petrone

e-mail:

investor.relations@pierrelgroup.com

Global Consult S.r.l.

Media Relations

Rossana Del Forno

e-mail:

areacomunicazione@globalconsultsrl.com



tel. +39 0823 626 111
fax +39 0823 626 228

tel. +39 333 6178665